Pluristem Therapeutics, Inc. (PSTI) Upgraded by Maxim Group to Buy
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) was upgraded by analysts at Maxim Group from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday. The brokerage presently has a $2.00 price target on the biotechnology company’s stock. Maxim Group’s price objective would indicate a potential upside of 51.52% from the stock’s current price.
The analysts wrote, “Summary We recently spent time with Pluristem’s management team in Israel and reviewed in detail the thinking behind the current Phase III trial design. Pluristem is focused on showing the benefits of therapy in prolonging the time to an event. If patients can keep a limb a year longer, is the therapy viable and does it create value. We do believe the current statistical plan is well designed to show if a difference exists in the time to event analysis. What will be critical will be if US regulators will accept time to event in place of AFS for approval. It stands to reason that a treatment effect which prolongs time to event, (as is the standard on oncology) could suffice for approval in CLI. i.e. if the treated group keeps limbs longer, is the therapy approvable one and is there benefit? We must also consider changes in the regulatory landscape and what impact the adaptive pathway and 21st Century Act might have on regenerative medicine – cell therapy approval timelines. Given the depressed market capitalization of the company, ~$120M range and the balance sheet, post raise, (~$35M) we believe there will be enough positive news flow to support an increase in valuation.””
A number of other research firms also recently commented on PSTI. Zacks Investment Research downgraded shares of Pluristem Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, April 13th. HC Wainwright restated a “buy” rating and set a $3.50 price target on shares of Pluristem Therapeutics in a report on Friday, May 5th.
Shares of Pluristem Therapeutics (NASDAQ PSTI) traded up 4.76% on Monday, reaching $1.32. 168,481 shares of the company’s stock were exchanged. Pluristem Therapeutics has a 1-year low of $1.04 and a 1-year high of $1.85. The stock’s 50-day moving average price is $1.36 and its 200-day moving average price is $1.33. The company’s market capitalization is $127.16 million.
Several large investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC raised its stake in Pluristem Therapeutics by 62.4% in the first quarter. Jane Street Group LLC now owns 108,830 shares of the biotechnology company’s stock worth $134,000 after buying an additional 41,796 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its stake in Pluristem Therapeutics by 46.0% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 92,000 shares of the biotechnology company’s stock worth $135,000 after buying an additional 29,000 shares in the last quarter. Menora Mivtachim Holdings LTD. purchased a new stake in Pluristem Therapeutics during the first quarter worth about $1,230,000. Finally, Renaissance Technologies LLC raised its stake in Pluristem Therapeutics by 9.1% in the first quarter. Renaissance Technologies LLC now owns 1,553,800 shares of the biotechnology company’s stock worth $1,911,000 after buying an additional 129,000 shares in the last quarter. Institutional investors and hedge funds own 3.79% of the company’s stock.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.